Denali Therapeutics (DNLI) Competitors $15.36 -0.14 (-0.90%) Closing price 04:00 PM EasternExtended Trading$15.18 -0.17 (-1.14%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, AXSM, RNA, and NUVLShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Axsome Therapeutics Avidity Biosciences Nuvalent Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment. Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -40.79% -36.39% Beam Therapeutics -661.31%-43.15%-31.06% Do analysts recommend DNLI or BEAM? Denali Therapeutics presently has a consensus target price of $33.50, suggesting a potential upside of 118.10%. Beam Therapeutics has a consensus target price of $48.45, suggesting a potential upside of 137.99%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07 Which has more volatility & risk, DNLI or BEAM? Denali Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Does the media refer more to DNLI or BEAM? In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Beam Therapeutics and 10 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.44 beat Beam Therapeutics' score of 0.92 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.79-$422.77M-$2.80-5.49Beam Therapeutics$63.52M32.42-$376.74M-$4.50-4.52 Do institutionals & insiders hold more shares of DNLI or BEAM? 92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryDenali Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.27B$3.17B$5.81B$10.01BDividend YieldN/A2.28%5.29%4.53%P/E Ratio-5.4921.3475.6926.28Price / Sales6.79469.04539.36121.13Price / CashN/A45.5837.2059.76Price / Book1.8010.0511.506.41Net Income-$422.77M-$53.33M$3.28B$270.56M7 Day Performance-0.58%2.18%1.30%3.01%1 Month Performance10.03%11.91%11.25%9.74%1 Year Performance-39.98%14.14%59.54%26.68% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.3749 of 5 stars$15.36-0.9%$33.50+118.1%-38.6%$2.27B$330.53M-5.49430News CoveragePositive NewsAnalyst ForecastBEAMBeam Therapeutics2.6639 of 5 stars$16.36-2.9%$48.45+196.2%-14.5%$1.66B$63.52M0.00510Analyst UpgradeROIVRoivant Sciences2.8812 of 5 stars$11.93-0.1%$16.50+38.3%+5.0%$8.15B$29.05M0.00860News CoverageOptions VolumeRVMDRevolution Medicines4.3735 of 5 stars$37.97-0.9%$69.92+84.2%-1.9%$7.10B$11.58M0.00250Positive NewsGRFSGrifols4.2084 of 5 stars$9.97+1.0%$10.30+3.3%+19.1%$6.85B$7.81B0.0023,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.098 of 5 stars$103.15-1.0%$101.57-1.5%+102.6%$6.85B$130.13M0.00140Positive NewsLEGNLegend Biotech3.4819 of 5 stars$34.73+1.0%$74.22+113.7%-28.3%$6.41B$627.24M0.002,609ABVXAbivax2.5988 of 5 stars$81.03-0.7%$92.33+13.9%+628.7%$6.12BN/A0.0061News CoveragePositive NewsAnalyst ForecastShort Interest ↓AXSMAxsome Therapeutics4.7504 of 5 stars$121.28-0.4%$178.00+46.8%+38.7%$6.05B$385.69M0.00380Positive NewsInsider TradeRNAAvidity Biosciences2.5988 of 5 stars$46.58-4.1%$67.00+43.8%+18.8%$5.99B$10.90M0.00190Insider TradeGap DownNUVLNuvalent2.8763 of 5 stars$76.58+0.7%$120.80+57.7%-7.4%$5.52BN/A0.0040News CoverageAnalyst Forecast Related Companies and Tools Related Companies Beam Therapeutics Competitors Roivant Sciences Competitors Revolution Medicines Competitors Grifols Competitors Rhythm Pharmaceuticals Competitors Legend Biotech Competitors Abivax Competitors Axsome Therapeutics Competitors Avidity Biosciences Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
